Positive

From Yahoo Finance: 2025-05-20 09:41:00

Carillon Tower Advisers released its first quarter 2025 investor letter, noting the S&P 500 Index’s 4.3% decline. Market volatility stemmed from policy uncertainties, economic slowdown, and AI investment concerns. Defensive sectors outperformed growth stocks, with energy, healthcare, and consumer staples leading. The quarter also saw a shift in index leadership towards a more diverse stock base.

In the same letter, Carillon Eagle Growth & Income Fund highlighted Abbott Laboratories (NYSE: ABT), a healthcare product manufacturer. Abbott Laboratories saw a one-month return of 2.90% and a 31.65% gain in the last 52 weeks, closing at $135.55 per share on May 19, 2025, with a market cap of $235.835 billion.

Carillon Eagle Growth & Income Fund praised Abbott Laboratories for its strong fourth-quarter results and 2025 guidance, leading to stock outperformance. The broader market rotation into healthcare and medical devices also boosted Abbott’s performance. Jim Cramer has praised Abbott Laboratories, calling it a ‘tour de force’ in the stock market.

Despite Abbott Laboratories not being among the 30 most popular stocks among hedge funds, 66 portfolios held the stock at the end of the fourth quarter. While Abbott Laboratories shows potential, investing in AI stocks might offer higher returns in a shorter timeframe. Investors seeking promising AI stocks can explore opportunities with less than 5 times earnings.



Read more at Yahoo Finance: Solid Results Boosted Abbott Laboratories’ (ABT) Performance in Q1